XML 20 R10.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue from Contracts with Customers
 9 Months Ended
Jan. 31, 2025
Revenue from Contract with Customer [Abstract]  
Revenue from Contracts with Customers Revenue from Contracts with Customers
Oncology Revenue
The following table represents disaggregated revenue for the three and nine months ended January 31, 2025 and 2024:
Three Months Ended
January 31,		Nine Months Ended January 31,
 2025202420252024
Pharmacology services$11,670 $11,184 $37,237 $33,919 
TOS license revenue4,500 — 4,500 — 
Other TOS revenue869 835 2,852 2,216 
Personalized oncology services— — — 18 
Total oncology revenue$17,039 $12,019 $44,589 $36,153 
Translational Oncology Solutions ("TOS") license revenue represents revenue from the sale of a license to access certain of the Company's PDX data. Other TOS revenue represents additional services provided to the Company's pharmaceutical and biotechnology customers, specifically flow cytometry services and software-as-a-service ("SaaS") provided via our Lumin Bioinformatics software ("Lumin").